Astrocytic 5-HT2B receptor as in vitro and in vivo target of SSRIs

Recent Patents on CNS Drug Discovery

Volumn 7, Issue 3, 2012, Pages 243-253

  Peng, Liang ^a   Huang, Jingyang ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

5 HT2B receptor; ADAR2; Astrocytes; cPLA2; GluK2; Major depression; SSRIs

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE; ADENOSINE DEAMINASES ACTING ON RNA; AMINE OXIDASE (FLAVIN CONTAINING); CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CITALOPRAM; DEXMEDETOMIDINE; FLUOXETINE; FLUVOXAMINE; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; GLUTAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; KETAMINE; METABOTROPIC RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PAROXETINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; REDOX EFFECTOR FACTOR 1; RILUZOLE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SERTRALINE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG;

ANHEDONIA; ARTICLE; ASTROCYTE; CALCIUM CELL LEVEL; CELL SELECTION; CHRONIC STRESS; CINGULATE GYRUS; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GLYCOGENOLYSIS; HABENULA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMBIC SYSTEM; MAJOR DEPRESSION; NONHUMAN; OLFACTORY NUCLEUS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA EDITING; SIGNAL TRANSDUCTION; SUBTHALAMIC NUCLEUS; TREATMENT DURATION; UPREGULATION;

ANIMALS; ASTROCYTES; DEPRESSIVE DISORDER, MAJOR; DRUGS, INVESTIGATIONAL; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; PATENTS AS TOPIC; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84867757383     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488912803252078     Document Type: Article

References (118)

1. 1A receptor mediated response by fluoxetine in rat brain. J Neural Transm 2000; 107: 377-87.
2. Kong EK, Peng L, Chen Y, Yu, ACH, Hertz, L. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem Res 2002; 27: 113-20.
3. Li B, Zhang S, Zhang H, Hertz L, Peng L. Fluoxetine affects GluK2 editing, glutamate-evoked Ca(2+) influx and extracellular signal-regulated kinase phosphorylation in mouse astrocytes. J Psychiatry Neurosci 2011; 36: 322-38.
4. Li B, Zhang S, Li M, Hertz L, Peng L. Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation. Psychopharmacol (Berl) 2009; 207: 1-12.
5. Li B, Dong L, Wang B, Cai L, Jiang N, Peng L. Cell type-specific gene expression and editing responses to chronic fluoxetine treatment in the in vivo mouse brain and their relevance for stressinduced anhedonia. J Neurochem Res 2012; in press.
6. Lovatt D, Sonnewald U, Waagepetersen HS, Schousboe A, He W, Lin JH, et al. The transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult murine cortex. J Neurosci 2007; 27:12255-66.
7. 2B-mediated SERT-independent SSRI target, slowly altering depression-associated genes and function. Current Signal Transduction Therapy 2012; 7: 65-80.
8. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008; 13: 501-10.
9. Altschuler SJ, Wu LF. Cellular heterogeneity: do differences make a difference? Cell 2010; 141: 559-63.
10. Barley K, Dracheva S, Byne W. Subcortical oligodendrocyte-and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr. Res 2009; 112: 54-64.
11. Hydén H, Lange PW. The effect of antiserum to S100 protein on behavior and amount of S100 in brain cells. J Neurobiol 1981; 2: 201-10.
12. Schroeter ML, Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009; 14: 235-37.
13. Benton CS, Miller BH, Skwerer S, Suzuki O, Schultz LE, Cameron MD, et al. Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains. Psychopharmacol (Berl) 2012; 221: 297-315.
14. Bilello, J., Pi, B. Multiple biomarker panel to stratify desease severity and monitor treatment of depression. US20110213219 (2011).
15. Diaz SL, Doly S, Narboux-Nême N, Fernández S, Mazot P, Banas SM, et al. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry 2012; 17: 154-63
16. Descarries L, Beaudet A, Watkins KC. Serotonin nerve terminals in adult rat neocortex. Brain Res 1975; 100: 563-388.
17. Saulin A, Savli M, Lanzenberger R. Serotonin and molecular neuroimaging in humans using PET. Amino Acids 2011; 42: 2039-57.
18. Zhou FC, Sari Y, Zhang JK. Expression of serotonin transporter protein in developing rat brain. Brain Res Dev Brain Res 2000; 119: 33-45.
19. Saurin AT, van der Waal MS, Medema RH, Lens SM, Kops GJ. Aurora B potentiates Mps1 activation to ensure rapid checkpoint establishment at the onset of mitosis. Nat Commun 2011; 2: 316.
20. Rattray M, Michael GJ, Lee J, Wotherspoon G, Bendotti C, Priestley JV. Intraregional variation in expression of serotonin transporter messenger RNA by 5-hydroxytryptamine neurons. Neurosci 1999; 88: 169-83.
21. Pickel VM, Chan J. Ultrastructural localization of the serotonin transporter in limbic and motor compartments of the nucleus accumbens. J Neurosci 1999; 19: 7356-66.
22. Yu PH, Hertz L. Differential expression of type A and type B monoamine oxidase of mouse astrocytes in primary cultures. J Neurochem 1982; 39: 1493-5.
23. Yu PH, Hertz L. Type A and B monoamine oxidase in glial cells in long term culture. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 687-90.
24. Eriksen JL, Gillespie RA, Druse MJ. Effects of in utero ethanol exposure and maternal treatment with a 5-HT(1A) agonist on S100B-containing glial cells. Brain Res Dev Brain Res 2000; 121: 133-43.
25. Hertz L, Lovatt D, Goldman SA, Nedergaard M. Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and[Ca(2+)]i. Neurochem Int 2010; 57: 411-20.
26. Wong DT, Threlkeld PG, Robertson DW. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacol 1991; 5: 43-7.
27. Li B, Zhang S, Zhang H, Nu W, Cai L, Hertz L, et al. Fluoxetinemediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacol (Berl) 2008; 201: 443-58.
28. Zhang S, Li B, Lovatt D, Xu J, Song D, Goldman SA, et al. 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotoninspecific reuptake inhibitors'. Neuron Glia Biol 2010; 6: 113-25.
29. Beck SG, Choi KC, List TJ. Comparison of 5-hydroxytryptamine1A mediated hyperpolarization in CA1 and CA3 hippocampal pyramidal cells. J Pharmacol Exp Ther 1992; 263: 350-9.
30. Hamon M, Gozlan H, el Mestikawy S, Emerit MB, Bolaños F, Schechter L. The central 5-HT1A receptors: pharmacological, biochemical, functional, and regulatory properties. Ann N Y Acad Sci 1990; 600: 114-29.
31. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X, et al. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 2000; 417: 181-94.
32. Bekar LK, He W, Nedergaard M. Locus coeruleus alphaadrenergic-mediated activation of cortical astrocytes in vivo. Cereb Cortex 2008; 18: 2789-95.
33. 2+ channels. Neurochem Int 1998; 32: 153-62.
34. 3H-ketanserin. J Neurosci 1989; 9: 3482-90.
35. Kursar JD, Nelson DL, Wainscott DB, Baez M. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol Pharmacol 1994; 46: 227-34.
36. Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, et al. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 1995; 115: 622-8.
37. Choi DS, Maroteaux L. Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain. FEBS Lett 1996; 391: 45-51.
38. 2+ responses in rat primary astrocyte cultures. J Neurosci Res 1993; 35: 246-56.
39. 2+ increases in cultured astrocytes from three different brain regions. Neurochem Int 2000; 36: 427-34.
40. Meier E, Hertz L, Schousboe A. Neurotransmitters as developmental signals. Neurochem Int 1991; 19: 1-15.
41. 2C receptors. Neurochem Int 2010; 57: 432-9.
42. 125I-lysergic acid diethylamide binds to a novel serotonergic site on rat choroid plexus epithelial cells. J Neurosci 1985; 5: 3178-83.
43. 1C receptors. Trends Pharmacol Sci 1990; 11: 181-2.
44. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. Obesity (Silver Spring) 2012; 20: 1426-36.
45. 2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A 1997; 94: 2036-40.
46. 2C receptor mRNA expression in rat prefrontal/frontal cortex and hippocampus. Neuropsychobiol 2011; 63: 160-8.
47. 2C): where structure meets function. Pharmacol Ther 1998; 79: 231-57.
48. 2C receptors in CHO-K1 cells. Br J Pharmacol 1999; 128: 13-20.
49. 2C receptor in glial cells. Brain Res Bull 1995; 38: 153-9.
50. Gibbs ME, Hertz L. Importance of glutamate-generating metabolic pathways for memory consolidation in chicks. J Neurosci Res 2005; 81: 293-300.
51. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011; 144: 810-23.
52. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, Murasawa S, Mori Y, Kosaki A, et al. Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int 2001; 60: 2153-63.
53. Manev H, Uz T, Smalheiser NR, Manev R. Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro. Eur J Pharmacol 2001; 411: 67-70.
54. Vollmayr B, Mahlstedt MM, Henn FA. Neurogenesis and depression: what animal models tell us about the link. Eur Arch Psychiatry Clin Neurosci 2007; 257: 300-03.
55. Mercier G, Lennon AM, Renouf B, Dessouroux A, Ramaugé M, Courtin F, et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004; 24: 207-16.
56. Perry KW, Fuller RW. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 1992; 50: 1683-90.
57. Neary JT, Kang Y, Tran M, Feld J. Traumatic injury activates protein kinase B/Akt in cultured astrocytes: role of extracellular ATP and P2 purinergic receptors. J Neurotrauma 2005; 22: 491-500.
58. Karege F, Perroud N, Burkhardt S, Fernandez R, Ballmann E, La Harpe R, et al. Alterations in phosphatidylinositol 3-kinase activity and PTEN phosphatase in the prefrontal cortex of depressed suicide victims. Neuropsychobiol 2011; 63: 224-31.
59. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007; 61: 240-5.
60. 2C receptor antagonist displaying broadbased antidepressant and anxiolytic properties in rodent models. Psychopharmacol (Berl) 2008; 199: 549-68.
61. Chanrion B, Mannoury la Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, et al. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol 2008; 73: 748-57.
62. Werneck AL, Rosso AL, Vincent MB. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. Arq Neuropsiquiatr 2009; 67: 407-12.
63. Millan MJ, Dekeyne A, Gobert A, Mannoury la Cour C, Brocco M, Rivet JM, et al. S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant(MK869) and paroxetine. Eur Neuropsychopharmacol 2010; 20: 599-621.
64. 2C receptor ligands. Scientific World Journal 2010; 10: 1870-85.
65. Rao JS, Ertley RN, Lee HJ, Rapoport SI, Bazinet RP. Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenomics J 2006; 6: 413-20
66. i in astrocytes mimic those of acute inhibition of TRPC1 channel activity. Cell Calcium 2011; 50: 42-53.
67. Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, Lee KU, et al. BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. Neuropsychobiol 2004; 49: 185-8.
68. Su KP, Huang SY, Peng CY, Lai HC, Huang CL, Chen YC, et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 2010; 67: v550-557.
69. 2 in the central nervous system: implication for neurodegeneration diseases. J Lipid Res 2004; 46: 205-13.
70. 2 does not participate in muscarinic receptor-mediated signaling in neurons. Brain Res 1998; 809: 18-30.
71. 2 in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells. J Biol Chem 2002; 277: 40384-9.
72. Allaman I, Fiumelli H, Magistretti PJ, Martin JL. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacol (Berl) 2011; 216: 75-84.
73. Little JT, Ketter TA, Kimbrell TA, Dunn RT, Benson BE, Willis MW, et al. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry 2005; 57: 220-8.
74. Videbech P. PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr Scand 2000; 101: 11-20.
75. Rasgon NL, Kenna HA, Geist C, Small G, Silverman D. Cerebral metabolic patterns in untreated postmenopausal women with major depressive disorder. Psychiatry Res 2008; 164: 77-80.
76. 2+ entry in cultured astrocytes. Biochem Biophys Res Commun 2005; 331: 603-13.
77. 2+ influx. Cell Calcium 2003; 33: 283-92.
78. Purdon AD, Rosenberger TA, Shetty HU, Rapoport SI. Energy consumption by phospholipid metabolism in mammalian brain. Neurochem Res 2002; 27: 1641-7.
79. Tharumaratnam D, Bashford S, Khan SA. Indomethacin induced psychosis. Postgrad Med J 2000; 76: 736-7.
80. Clunie M, Crone LA, Klassen L, Yip R. Psychiatric side effects of indomethacin in parturients. Can J Anaesth 2003; 50: 586-8.
81. Jiang HK, Chang DM. Non-steroidal anti-inflammatory drugs with adverse psychiatric reactions: five case reports. Clin Rheumatol 1999; 18: 339-45.
82. Adamczyk P, Goda A, McCreary AC, Filip M, Przegaliski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 2008; 59: 217-28.
83. Bass BL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Bioche 2002; 71: 817-46.
84. Valente L, Nishikura K. ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. Prog Nucleic Acid Res Mol Biol 2005; 79: 299-338.
85. Chen CX, Cho DS, Wang Q, Lai F, Carter KC, Nishikura K. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single-and double-stranded RNA binding domains. RNA 2000; 6: 755-67.
86. Kawahara Y, Ito K, Sun H, Ito M, Kanazawa I, Kwak S. Regulation of glutamate receptor RNA editing and ADAR mRNA expression in developing human normal and Down's syndrome brains. Brain Res Dev Brain Res 2004; 148: 151-5.
87. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem 1984; 42: 1-11.
88. Perea G, Araque A. GLIA modulates synaptic transmission. Brain Res Rev 2010; 63: 93-102.
89. Hertz L. Brain glutamine synthesis requires neuronal aspartate: a commentary. J Cereb Blood Flow Metab 2011; 31: 384-7.
90. Zarate CA Jr, Brutsche NE, Ibrahim L. Replication of Ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71: 939-46.
91. Owen RT. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole. Drugs Today (Barc) 2012; 48: 469-78.
92. C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol Psychiatry 2012; 71: 1022-5.
93. Yoshizumi M, Eisenach JC, Hayashida K. Riluzole and gabapentinoids activate glutamate transporters to facilitate glutamate-induced glutamate release from cultured astrocytes. Eur J Pharmacol 2012; 677: 87-92.
94. Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacol 2010; 35: 834-46.
95. Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010; 15: 501-11.
96. Song D, Li B, Yan E, Man Y, Wolfson M, Chen Y, et al. Chronic treatment with anti-bipolar drugs causes intracellular alkalinization in astrocytes, altering their functions. J Neurochem Res 2012; in press.
97. Barbon A, Popoli M, La Via L, Moraschi S, Vallini I, Tardito D, et al. Regulation of editing and expression of glutamate alpha-aminopropionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol Psychiatry 2006; 59: 713-20.
98. Delorme R, Krebs MO, Chabane N, Roy I, Millet B, Mouren-Simeoni MC, et al. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. Neuroreport 2004; 15: 699-702.
99. Sampaio AS, Fagerness J, Crane J, Leboyer M, Delorme R, Pauls DL, et al. Association between polymorphisms in GRIK2 gene and obsessive-compulsive disorder: a family-based study. CNS Neurosci Ther 2011; 17:141-7.
100. Jane DE, Lodge D, Collingridge GL. Kainate receptors: Pharmacology, function and therapeutic potential. Neuropharmacol 2009; 56: 90-113.
101. Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 1998; 54: 581-618.
102. Strutz-Seebohm N, Seebohm G, Shumilina E. Glucocorticoid adrenal steroids and glucocorticoid-inducible kinase isoforms in the regulation of GluR6 expression. J Physiol 2005; 565: 391-401.
103. Brand-Schieber E, Lowery SL, Werner P. Select ionotropic glutamate AMPA/kainate receptors are expressed at the astrocyte-vessel interface. Brain Res 2004; 1007: 178-82.
104. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 2008; 28, 264-78.
105. Egebjerg J, Heinemann SF. Ca 2+ permeability of unedited and edited versions of the kainate selective glutamate receptor GluR6. Proc Natl Acad Sci U S A 1993; 90: 755-9.
106. Ben Achour S, Pascual O. Astrocyte-Neuron Communication: Functional Consequences. Neurochem Res 2012 Jun 6.
107. Booher J, Sensenbrenner M. Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiol 1972; 2: 97-105.
108. Schousboe A, Fosmark H, Hertz L. High content of glutamate and of ATP in astrocytes cultured from rat brain hemispheres: effect of serum withdrawal and of cyclic AMP. J Neurochem 1975; 25: 909-911.
109. Hertz L, Schousboe A, Boechler N, Mukerji S, Fedoroff S. Kinetic characteristics of the glutamate uptake into normal astrocytes in cultures. Neurochem Res 1978; 3: 1-14.
110. Hertz E, Hertz L. Polarographic measurement of oxygen uptake by astrocytes in primary cultures using the tissue culture flask as the respirometer chamber. In vitro 1979; 15: 429-36.
111. Juurlink BHJ, Hertz L. In: Boulton AA, Baker GB, Walz W, Eds. Neuromethods: vol. 23, Cell Cultures. NY: Humana Clifton 1992: 269-321.
112. Foo LC, Allen NJ, Bushong EA, Ventura PB, Chung WS, Zhou L, et al. Development of a method for the purification and culture of rodent astrocytes. Neuron 2011; 71: 799-811.
113. Kimelberg HK. Functions of mature mammalian astrocytes: a current view. Neuroscientist 2010; 16: 79-106.
114. Peng L, Arystarkhova E, Sweadner KJ. Plasticity of Na, K-ATPase isoform expression in cultures of flat astrocytes: species differences in gene expression. Glia 1998; 24: 257-271.
115. Porter JT, McCarthy KD. Adenosine receptors modulate[Ca2+]i in hippocampal astrocytes in situ. J Neurochem 1995; 65: 1515-23.
116. Peng L, Martin-Vasallo P, Sweadner KJ. Isoforms of Na, K-ATPase alpha and beta subunits in the rat cerebellum and in granule cell cultures. J Neurosci 1997; 17: 3488-502.
117. Dave V, Kimelberg HK. Na(+)-dependent, fluoxetine-sensitive serotonin uptake by astrocytes tissue-printed from rat cerebral cortex. J Neurosci 1994; 14: 4972-86.
118. 2B serotonergic signaling. Neurochem Int 2010; 57: 421-31.